Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Megan E. Capozzi,1 Richard D. DiMarchi,2,3 Matthias H. Tschöp,4,5 Brian Finan,3 and Jonathan E. Campbell1

1Duke Molecular Physiology Institute, Duke University, Durham, North Carolina 27701; 2Department of Chemistry, Indiana University, Bloomington, Indiana 47705; 3Novo Nordisk Research Center, Indianapolis, Indiana 46241; 4Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764 Neuherberg, Germany; and 5Division of Metabolic Diseases, Department of Medicine, Technische Universität München, 80333 Munich, Germany

ABSTRACT Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia. However, the activity of glucagonlike peptide 1 receptor–directed strategies is submaximal, and the only potent, sustainable treatment of metabolic dysfunction is bariatric surgery, necessitating the development of unique therapeutics. GLP-1 is structurally related to glucagon and glucose-dependent insulinotropic peptide (GIP), allowing for the development of intermixed, unimolecular peptides with activity at each of their respective receptors. In this review, we discuss the range of tissue targets and added benefits afforded by the inclusion of each of GIP and glucagon. We discuss considerations for the development of sequence-intermixed dual agonists and triagonists, highlighting the importance of evaluating balanced signaling at the targeted receptors. Several multireceptor agonist peptides have been developed and evaluated, and the key preclinical and clinical findings are reviewed in detail. The biological activity of these multireceptor agonists are founded in the success of GLP-1-directed strategies; by including GIP and glucagon components, these multireceptor agonists are thought to enhance GLP-1’s activities by broadening the tissue targets and synergizing at tissues that express multiple receptors, such as the brain and pancreatic islet β cells. The development and utility of balanced, unimolecular multireceptor agonists provide both a useful tool for querying the actions of incretins and glucagon during metabolic disease and a unique drug class to treat type 2 diabetes with unprecedented efficacy. (Endocrine Reviews 39: 719 – 738, 2018)

Type 2 diabetes (T2D) is a complex, multifaceted disease that has rapidly increased in prevalence, currently affecting 1 in 11 adults worldwide, and a substantial economic burden with a global cost of $1.3 trillion US (1). Although the World Health Organization classifies diabetes as the sixth leading cause of death worldwide, the contribution of diabetes to heart disease (first leading cause of death) and stroke (second leading cause of death) significantly increases the impact of this disease on overall mortality rates.

Although far from understood, T2D typically arises following the development of insulin resistance, along with dysfunctional pancreatic islet action (insufficient insulin production and excessive glucagon production). Despite the recognized complexity of T2D pathogenesis, current therapeutic strategies are targeted at single disease aspects. Many therapeutic agents aim to enhance insulin levels with administration of exogenous insulin or insulin secretagogues, while others target insulin sensitivity (i.e., peroxisome proliferator–activated receptor γ agonists). Following the discovery of leptin, and later ghrelin, it became clear that hormonal signals to the brain play an important role in the development of obesity and subsequent T2D. Thus, targeting the central nervous system (CNS) to manage weight by increasing energy expenditure and restricting caloric intake emerged as an efficacious component of a successful weight loss strategy. Indeed, the mechanism for glucagonlike peptide 1 receptor (GLP-1R) agonists has been broadened beyond actions in the pancreas, to include CNS activity that reduces food intake and facilitate weight loss. Consequently, it has become clear that the multifaceted nature of T2D demands a therapeutic strategy that is equally sophisticated, and thereby provides synergistic avenues to target the many pathogenic origins of the disease.

doi: 10.1210/er.2018-00117 https://academic.oup.com/edrv 719
Bariatric surgery has proven to be both efficacious and sustainable for the treatment of T2D. Originally developed specifically for morbidly obese individuals, independent of metabolic dysfunction, it quickly became clear that bariatric surgery can induce rapid improvements in hyperglycemia. Available pharmaceutical interventions are not able to replicate the magnitude of the benefits associated with surgery. On the other hand, it is not economically feasible to perform bariatric surgery as a primary treatment option for the number of people with T2D, creating a significant need for the development of pharmaceutical agents that achieve similar efficacy as surgical options, working noninvasively to target several tissues in a complimentary, synergistic manner.

Incretin hormones, glucagonlike peptide-1 (GLP-1), and glucose-dependent insulinotrophic peptide (GIP) have recently garnered attention for their broad effects on target tissues of diabetes. Most notably, these factors are crucial for postprandial rises in insulin secretion. In fact, 50% to 70% of insulin secretion following a meal is a result of incretin action. Yet in T2D, the incretin effect is significantly blunted, suggesting that lesions in this axis may be key in the development of the disease and that restoration of incretin signaling could be particularly effective as a treatment strategy (2, 3). In addition to incretin peptides, glucagon has reemerged as a significant contributor to glucose homeostasis and energy metabolism. Physiologically, glucagon opposes insulin action and increases glycemia, sparking numerous efforts to inhibit its action and lower glucose (4). However, the impact of glucagon on energy metabolism is becoming more evident, with increasing efforts now being put forth to agonize the glucagon receptor in an effort to treat metabolic dysfunction (5). What is clear is that both incretin peptides and glucagon are substantially increased following bariatric surgery (6–9), igniting interests in these peptides as the mechanism for the improvements in metabolic dysfunction. This has also made clear that our understanding of how these gut-derived peptides influence systemic metabolism is not completely understood. This review will discuss the controversies currently presiding over these peptides, and attempt to reconcile their contribution to both the pathogenesis of T2D and their potential to contribute to the next generation of therapeutic agents for the treatment of the disease.

**Current Incretin-Directed Therapeutic Strategies**

**GLP-1R agonists and dipeptidyl peptidase-4 inhibitors**

Dipeptidyl peptidase-4 (DPP4) is an exopeptidase that cleaves a wide range of peptide targets, including GLP-1 and GIP, thereby limiting their activity (10). Whereas DPP4 cleaves many peptides, the DPP4 inhibitors (DPP4i) lower glycemia solely by enhancing the biological activity of GLP-1 and GIP (11). The DPP4 inhibitor sitagliptin was approved for clinical use in 2006, and additional DPP4 inhibitors have since been introduced into the clinic. Although generally considered safe, these inhibitors have modest effects on hemoglobin A1c (HbA1c) and are weight neutral when administered as monotherapy. An important limitation of this drug class is that it requires endogenous production of incretins. Indeed, supraphysiologic levels of active GLP-1, beyond the concentrations typically achieved with DPP4i, are necessary to achieve robust effects on glycemia and stimulate a decrease in body weight.

There are currently several GLP-1 receptor agonists available for the treatment of T2D, which are more efficacious in controlling glycemia. These GLP-1 analogs are modified to prevent inactivation by DPP4 and substantially elongate the half-life of active GLP-1 in circulation. In addition to providing glucose control, several large-scale cardiovascular outcome trials have demonstrated that certain GLP-1R agonists reduce cardiovascular events (12–16). Thus, GLP-1 has many target tissues, and benefits of its use are observed across several aspects of the metabolic syndrome. Despite the broad range of benefits from GLP-1R monoagomist, there are limitations to its use that prevent maximal achievable benefits. Most notably, gastrointestinal side effects such as nausea
limit the tolerability of GLP-1R agonists. As a consequence, these treatments are administered at submaximal doses in terms of their effect on weight loss and have to be dose titrated during initial administrations to patients (17), highlighting the potential for additional benefits beyond what is currently being achieved in the clinic.

**Bariatric surgery**

The single most effective therapy for T2D is bariatric surgery, predominantly manifested as Roux-en-Y and vertical sleeve gastrectomy procedures. It is now appreciated that the benefits of bariatric surgery are not solely dependent on dietary limitations and subsequent weight loss. Both Roux-en-Y and vertical sleeve gastrectomy yield immediate, weight-independent metabolic benefits and have since been termed “metabolic surgeries” (18). Although the molecular mechanisms underlying these effects are incompletely understood, several gastrointestinal hormones, including GLP-1, GIP, glucagon, oxynotomodulin, peptide YY, and ghrelin, are altered as a result and have been implicated as part of the mechanism. Attempts to isolate a singular peptide or metabolite as the primary stimulus for the improvement in metabolism following bariatric surgery have largely been unsuccessful (19–23). A takeaway from these studies is that the metabolic changes following bariatric surgery are multifaceted and complex, and therefore may require more than manipulation of a singular metabolic pathway to recapitulate the full efficacy of the surgery. Moreover, a key attribute to the success of bariatric surgery is that it causes negative energy balance while simultaneously decreasing appetite, a feat that no other weight loss strategy can achieve, and this is likely due to collaboration of multiple hormonal factors to manipulate these opposing behaviors coincidently.

**Need for Novel Therapeutics**

Despite the unprecedented benefits of bariatric surgeries, their application is not widespread enough to manage the T2D epidemic. The surgeries are expensive and invasive and are accompanied by several complications, including dumping syndrome, diarrhea, and hypoglycemia, among others. Furthermore, there are physical constraints for providing this surgery, including insufficient numbers of available surgeons with technical expertise and lack of appropriate infrastructure to perform the surgeries (24). These important limitations of bariatric surgery provide the impetus to develop pharmaceutical mimetics that provide broad systematic targeting to maximize efficacy while minimizing invasiveness. Several groups have approached this need by developing multitarget agonists largely centered on hormonal gut peptides. Although many combinatorial therapies have been pursued, and their development discussed in other reviews (24–26), this review will focus on incretin-based multiagonists. The basis for these compounds is anchored in the success and safety of GLP-1R agonists. This particularly pertains to the outcomes regarding neurologic and cardiovascular side effects, while still activating several tissue targets to improve metabolism. Incretins also improve glycemia without carrying hypoglycemic risk because their insulin-inducing activities are glucose dependent, further providing safety compared with other drug classes, such as sulfonylureas. Lastly, recent studies have demonstrated synergistic effects on glycemia and body weight when receptor agonism is balanced (27, 28), which provides the basis for the development and translation of several multiagonist compounds discussed herein.

**Incretin/Glucagon Biology**

The purpose of this chapter is to provide a cursory review of relevant pathways modulated by GLP-1, GIP, and glucagon receptor activation to support their potential for use in multireceptor agonism. The review is limited to these three peptides due to their complimentary activities and similar structures at the N-terminal region that have allowed for the development of sequence-intermixed peptide therapies. GLP-1, GIP, and glucagon exert their effects through similar mechanisms of action, all acting on class B G protein–coupled receptors (GPCRs) of the G family and typically mediating signal transduction through the stimulation of cAMP. However, the tissue-specific distribution of the incretin/glucagon cognate receptors is unique, and likely plays a role in the variation in their respective functions (Fig. 1). For example, whereas GLP-1, GIP, and glucagon all have insulinotropic effects on the pancreatic β cell, only glucagon can stimulate hepatic glucose production, whereas the GLP-1R and GIP receptor (GIPR) are not expressed in hepatocytes. Furthermore, even within a tissue type that expresses all three receptors (e.g. β cells), there appear to be unique characteristics for each receptor. Together, this raises the intriguing possibility for synergistic interactions, both at the cellular, tissue, and systemic levels. Herein, we describe the relevant activities of each peptide, highlighting areas of activity that are more appropriately addressed through combinatorial treatment strategies.

**GLP-1**

GLP-1 is secreted following posttranslational processing of proglucagon by prohormone convertase 1/3 in enteroendocrine i-cells and possibly pancreatic α cells (29, 30). The secretion of GLP-1 from the intestine comprises the classic incretin response to ingested nutrients, while the significance of α cell–derived GLP-1 was first identified in the early 1980s and...
was subsequently found to stimulate insulin secretion in a glucose-dependent manner in 1987 (31, 32). GLP-1 offers added metabolic benefits beyond its effect on insulin secretion, also slowing gastric emptying, suppressing appetite, and lowering body weight. Recent insights have begun to describe anti-inflammatory actions of GLP-1R agonists (33, 34), and although GLP-1R therapies have shown beneficial impact on cardiovascular events, the mechanisms by which this occurs are largely unknown (35). Comprehensive reviews of the metabolic actions of GLP-1 have been discussed previously (36-39).

Recent advances in optimizing GLP-1R agonist therapies to improve efficacy and adherence include enhancing the bioavailability for longer duration and allowing for oral delivery. Protracted GLP-1R agonists have not only improved convenience for patients by lessening the frequency of administration but have also shown unprecedented glycemic and body weight efficacy in clinical trials (14, 40-47). After 10 years of clinical use, GLP-1R agonists and DPP-4i are generally considered safe therapies. Compared with other therapeutic options, GLP-1R agonists present low risk of hypoglycemia, good efficacy for glycemic control and weight loss, and improvements in cardiometabolic health. These attributes have positioned GLP-1 as a favored candidate for the foundation of multireceptor agonists.

GIP
GIP, a 42–amino acid peptide, is secreted by K cells in the intestine in response to nutrients. GIP was discovered in 1973 and originally termed gastric inhibitory peptide due to its effects on gastric acid secretion. Shortly after its discovery, it was found to stimulate insulin in a glucose-dependent manner (48), and thus its role as an incretin hormone has been the primary focus for characterization of its activities. GIP exerts its actions through the GIPR, a seven-transmembrane heterotrimeric GPCR of the Gs family. GIPR is widely expressed, including but not limited to the pancreas, stomach, bone, small intestine, adipose tissue, lung, and multiple regions of the CNS (49). The most well-defined activity of GIP is its glucose-dependent insulinotropic activity in the pancreas. GIP stimulates insulin secretion through GIPR on the β cell, activating cAMP/protein kinase A- and cAMP/Epac2-dependent pathways in the β cell (50). Consistent with its role as an incretin, Gipr−/− mice exhibit impaired oral glucose tolerance, although intraperitoneal glucose tolerance is unaffected (51). Interestingly, DPP-4i retained their ability to stimulate insulin secretion and lower glycemia in β-cell–specific Gipr knockout mice (52), but not β-cell–specific Gipr knockout mice (53), under chow-fed conditions. This raises the intriguing possibility that enhanced GIPR

Figure 1. Glucagon, GLP-1, and GIP have unique activities at different tissue beds. Blue arrows show the effects of glucagon, green arrows show GLP-1 effects, and red arrows show GIP effects. Although there are overlapping activities of these peptides in the brain and pancreas, the majority of tissues have nonoverlapping receptor expression, yielding unique activities of each peptide at different tissues. Therefore, multireceptor agonists demonstrate additive effects, in part, by engaging a broader range of activities.
activity may constitute the majority of the glucoregulatory actions of DPP4 inhibitors under normal conditions. Whether this relationship is altered by metabolic stress remains to be seen, which is important to understand given that GIP-stimulated insulin secretion is substantially blunted in people with T2D, even at pharmacological levels (54).

Although GIPR and GLP-1R are structurally related and exhibit comparable activity for glucose-stimulated insulin secretion, divergent pathways have been identified related to β-cell survival. GIP signaling through its cognate receptor promotes β-cell survival and protects against streptozotocin-induced β-cell apoptosis through ERK-dependent pathways that converge on Tcf7 expression, which encodes the TCF1 protein (53). Similarly, Tcf7−/− mice are more susceptible to streptozotocin-induced β-cell apoptosis and exhibit impaired glucose tolerance in response to aging or high-fat diet feeding (53). This pathway was unaffected by loss of GLP-1R stimulation with Ex-4, demonstrating unique actions of these receptors. This demonstrates the benefit of activating multiple incretin receptors in the β cell, despite certain converging activities, such as insulin secretion.

**Limitations for the development of GIPR agonists**

The development of GIP-directed therapies has been limited by several findings. Most notably, insulin secretion in response to GIP administration is impaired in patients with T2D, and although GLP-1-induced insulin secretion is also reduced in these patients, the amount of insulin secretion is still functionally relevant (54). This finding naturally steered the field to develop GLP-1-directed therapies. However, it is important to note that the responsiveness to GIP is reversible. Alleviation of hyperglycemia can reensitize the islet to GIP, at least in part due to restoration of GIPR expression in the islet (55, 56). Hyperglycemia induced by partial pancreatectomy reduced both islet Giptr and Gipr, but receptor expression was restored by reducing hyperglycemia with phlorizin (55). Similarly, phlorizin treatment of hyperglycemic Zucker diabetic fatty rats for 14 weeks restored GIPR expression from ~20% of lean control levels to ~80% (56). This finding is pertinent to humans; restoration of GIP-induced insulin secretion was demonstrated in T2D patients following intensive insulin therapy for 4 weeks (57). Understanding the mechanisms that facilitate a strong correlation between GIPR activity and β-cell function may provide key insight into the etiology of β-cell dysfunction in T2D. Moreover, the plasticity of GIPR signaling in β cells indicates that therapies incorporating GIPR activity may provide additional glucose-lowering effects, particularly if GIP agonism is combined with additional agents such as GLP-1.

Another limitation in the pursuit of GIP-directed therapies was the observation that GIP stimulates triacylglycerol deposition in adipocytes. Initial studies utilizing Gipr−/− mice revealed that germ-line deletion of GIPR prevented obesity following high-fat feeding or in the context of leptin deficiency, concluding that GIP was a lipogenic hormone (58). Notably, this effect is dependent on the type of dietary challenge: Gipr−/− mice fed a high-carbohydrate diet are not resistant to weight gain (59). Caution should be used in the interpretation of germ-line knockout models due to confounding effects of compensatory mechanisms. For instance, Glp1r−/− mice also show profound protection against diet-induced obesity (DIO) (60), yet GLP-1R agonists are now used in clinic to induce weight loss in obese individuals independent of metabolic dysfunction (61). Subsequent studies using pharmacological antagonism of GIPR with a modified GIP peptide, (Pro3)GIP, in obese animals also concluded that loss of GIPR function can limit or reduce adiposity (62, 63). However, these conclusions were recently challenged by the findings that (Pro3)GIP is a full agonist at the human GIPR and a partial agonist at the rodent GIPR (64). Studies in humans demonstrate GIP agonism increases adipose tissue blood flow, events that are postulated to facilitate lipogenesis (65–67). Although establishing causality between adipose tissue blood flow and adipogenesis as a bone fide action of GIP still remains to be done, these studies did use newer GIPR antagonists that could prove to be beneficial for future efforts aimed at addressing this and other GIP actions.

In fact, there are efforts to test the use of GIPR antagonism as a therapeutic strategy for limiting obesity, because loss of GIPR signaling is suggested to prevent triacylglycerol uptake (68, 69). More thorough studies comparing GIPR agonism and antagonism are necessary to elucidate the impact of extrapancreatic GIP signaling (Fig. 2). Together, the major observations leading to the conclusion that GIP is obesogenic have significant limitations that preventing clear insight in this question.

Human and rodent adipocytes do express a GIPR, which has been reported to stimulate lipoprotein lipase, and mechanistic studies in adipocyte cell lines indicate a lipogenic signal for GIPR activation (70, 71). Notably, the effects of GIP on isolated adipocytes were dependent on insulin, thus making it difficult to dissociate the lipogenic effects of GIP mediated through direct actions on adipocytes from those mediated indirectly through the insulinotropic effects of GIP in β cells. Indeed, insulin appears to be a primary driver of obesity, at least in rodents (72). Even more complexity was added when subsequent studies demonstrated that Gipr−/− mice fed a high-fat diet gained less body weight than wild-type mice primarily due to differences in lean mass (73). Furthermore, rescue of Gipr specifically in the adipose tissue of the knockout mice corrected this difference in lean mass. Supporting the important role for GIPR signaling in adipose, a genome-wide association study assessing
heritability of human obesity identified a unique body mass index–associated locus near GIPR (74). Taken together, the effect of GIP on lipid deposition in adipose remains unclear and further studies utilizing adipocyte-specific knockout models or highly specific GIPR antagonists are required to better understand the significance of GIPR activity in adipose tissue.

GIPR is expressed in the α cells of both mouse and human islets, and its activation has been linked to glucagon secretion (75, 76). In normal, healthy patients, GIP infusion elevated serum glucagon levels; however, this was observed in hypoglycemic and euglycemic conditions, but not during hyperglycemia (76). Notably, despite the elevated glucagon levels, glucose infusion rates in clamps were higher with GIP infusion, suggesting that at least in healthy patients, the glucagon-inducing activity of GIP does not have negative effects on glycemia. Furthermore, these findings did not correlate with insulin levels, which were significantly elevated by GIP infusion under all glycemic conditions. Whether GIP-induced glucagon secretion meaningfully impacts physiology requires further study.

**Extrapancreatic effects of GIP**

GIP-directed therapies may have added benefits beyond its effects on glycemia through activation of GIPR in extrapancreatic tissues. One such target is the bone, where GIP has been suggested as the key component of a posited “entero-osseous axis” (77). Proper bone health requires a balance between bone resorption by osteoclasts and bone formation by osteoblasts. Following a meal, bone resorption is suppressed, shifting the balance to bone formation and strengthening, suggesting that postprandial signals may be key mediators of this transition. Bone GIPR expression was first observed in 2000, with expression in osteoclasts, osteoblasts, and osteocytes (78). Studies performed in Gipr−/− mice confirmed the importance of GIP signaling for bone homeostasis; bone length and width were decreased, with lowered bone mineral content and density in Gipr−/− compared with wild-type controls (79). It remains unclear if GIP has a direct effect on osteocytes, or if the effect in the knockout mice is due to differences in circulating insulin. Indeed, insulin is known to be an integrator of nutrition and bone homeostasis (80). The role of GIP signaling has also been confirmed in patients. The effect of a genetic variant that exhibits reduced GIP activity, GIPR Glu354Gln, was assessed in perimenopausal women, who are at increased risk for osteoporotic fractures. Women with the loss-of-function variant were about 50% more likely to experience nonvertebral fractures and had significantly lower hip and femoral neck bone mineral density (81). Additional studies assessing the circulating biomarker of bone resorption, carboxy-terminal collagen cross-links, have demonstrated a strong relationship between GIP and nutrient-induced bone strengthening (82). Evidence for a direct effect of GIP in bone was seen in C-peptide-negative type 1 diabetic patients, where similar suppression of collagen crosslinks occurred independent of changes in circulating insulin (82). Thus, GIP may be a critical factor linking meal intake and bone formation. Notably, bariatric surgery or hypocaloric diets reduce bone mineral density in...
both rodents and patients (83–86). This raises the intriguing possibility that having a GIP-directed component in a mixed-agonist treatment strategy could reduce the adverse effects on bone that arise due to rapid weight loss or reduced calorie intake. However, it is important to note that GIP is also elevated following bariatric surgery (87), whereas bone mineral density is reduced; further work is necessary to elucidate the the direct and indirect effects of GIP on bone health in the context of obesity and T2D.

GIPR is expressed in both rodent and human cardiomyocytes and is linked to cardiac lipid metabolism. Gipr−/− mice were protected from ischemic cardiac injury, and this effect was independent of GIP-stimulated insulin secretion (88). The protection exerted by GIPR deletion was mediated by decreased hormone-sensitive lipase phosphorylation and increased myocardial TAG content. However, GIP agonism had no effect on cardiac ischemia, despite stimulating hormone-sensitive lipase phosphorylation and fatty acid oxidation, demonstrating the cardiac safety of GIPR agonism for use in multireceptor agonism. In fact, GIP administration limited angiotensin II–stimulated cardiac hypertrophy and fibrosis (89). However, it is unclear whether this occurs through direct effects on cardiac GIPR or indirectly through activation of insulin in vivo. Future studies are still necessary to characterize the effect of GIPR signaling in acute ischemic injuries.

**Glucagon**

Glucagon is a 29–amino acid peptide derived from posttranslational processing of the proglucagon protein by prohormone convertase 2. It signals through the seven-transmembrane glucagon receptor (GCGR), which is widely expressed throughout the body, including liver, brain, heart, kidney, adipose tissue, and pancreatic β cells (90). The hyperglycemic effect of glucagon mediated through its direct stimulation of glycogenolysis in the liver was determined 70 years ago (91), and later glucagon was demonstrated to elevate glucose through the stimulation of gluconeogenesis in the liver. On the other hand, glucagon, like incretins, was found to possess glucose-dependent insulinotropic activities. Despite this behavior, the focus of glucagon has been on its elevated levels observed in diabetes, which tightly correlate with dysglycemia (92, 93). As a result, much of the early efforts on glucagon-based therapies have been focused on blockade of glucagon receptor. Seminal studies demonstrated that either pharmacological or genetic blockade of glucagon action in streptozotocin-induced diabetes completely normalizes glucose (94–96). This concept appears to translate to humans, where glucagon receptor antagonists in clinical trials are efficacious in lowering HbA1c (97, 98). However, these agents have stalled in their development due to a number of undesirable effects including elevated aspartate aminotransferase/alanine aminotransferase levels, accumulation of liver triglycerides, and hyperglucagonemia.

In addition to hepatocytes, glucagon receptors have been reported to be expressed in the brain, although the biological significance of GCGR activation in neuronal tissues remains unclear. Central activation of the GCGR stimulates a broad range of beneficial actions for obesity management, including satiety and energy expenditure. Glucagon levels increase in response to a protein-rich meal (99), and inhibiting glucagon’s action can increase food intake (100). Early studies also indicated an effect of glucagon on body weight, independent of food intake (101). This effect has since been attributed to the thermogenic effect of glucagon, as administration of glucagon to rats increased brown adipose tissue oxygen consumption and temperature (102). Similar effects have been observed in humans, but only during relative hypoinsulinemia (103). Induction of fibroblast growth factor 21 (FGF21) is implicated in glucagon’s weight-lowering effects in rodents and humans (104). Glucagon stimulates FGF21 secretion from hepatocytes, and FGF21 exerts similar biological effects of glucagon, including increased energy expenditure (105).

Though paradoxical, postprandial hyperglucagonemia is commonly observed following bariatric surgery (106–109). Based on studies from total pancreatectomized humans, which cannot produce islet-derived hormones, it has been confirmed that the intestine can be a source of circulating glucagon (110). Notably, glucagon was secreted in response to oral glucose administration in these patients, similar to GLP-1. Thus, it could be speculated that this intestinal source of glucagon is elevated following bariatric surgery. Moreover, the hyperglucagonemia as a result of extrapancreatic glucagon production may contribute to the beneficial effects on energy expenditure observed. Following surgery, glucagon hypersecretion would occur in the presence of postprandial insulin secretion due to a restored incretin response, thereby balancing the negative effects of glucagon on hepatic glucose production. Conversely, in T2D patients without surgery, hyperglucagonemia occurs in the absence of adequate insulin secretion, thereby promoting hepatic glucose output (111). The significance of gut-derived glucagon has yet to be elucidated, but is actively being pursued.

**Current Dual Agonists and Triagonists**

Although GLP-1, GIP, and glucagon have some overlapping functionality, their combined use leads to synergistic effects on diabetes and related metabolic disease. Although there is biological justification for the development of multireceptor agonist therapies, several design characteristics are important to achieve maximal efficacy. This section will focus on the following considerations for creation of multireceptor agonists (1)
structural design of effective agonists; (2) optimization of agonist activities at each receptor; and (3) efficacy of recently developed dual agonists and triagonists that use GLP-1, GIP, and glucagon receptor signaling.

Considerations for the discovery and development of multiagonist therapies

Unimolecular design: sequence-intermixed hybrids vs multivalent fusions

The most prevalent argument in favor of single-molecule multiagonists vs combination of mono-agonists has centered on the pragmatic challenge of developing and registering a single compound as opposed to multiple compounds. Downstream considerations also include eventual pricing and cost of goods for production. The clinical development of combinations requires that each individual component must be studied in isolation first for clinical safety, and perhaps for efficacy, before it is studied in combination. Optimally, these combinations would also be formulated together in a single physical mixture such that it will be administered as a single injection. Formulations are finely tuned to support the storage stability and absorption following injection of a particular drug. Oftentimes this recipe is unique to a certain drug product, and not compatible with other compounds, which may limit a single formulation. Therefore, if the eventual products are aimed to be mixed together, then early chemistry efforts are necessary to ensure compatible coformulation. Furthermore, drug–drug interactions in a coformulation can influence biophysical stability, and thus the potential to alter efficacy after drug administration. One major advantage of physical mixtures or loose combinations is that it should be easier to titrate the components to achieve maximal effectiveness and safety, particularly if one of the ingredients has a narrow therapeutic window, as in the case of glucagon. Secondary to that consideration is the simpler chemical optimization of a monomolecular mixed agonist vs a mixed agonist. Pharmacokinetic differences between the combination products, most notably different half-lives and biodistribution, may drive differential efficacy and constitute another way to realize altered ratio of in vivo activities, including humans. Single-molecule mixed agonists can also present different biodistribution than combinations, such that a specific component of the single molecule could be the dominant factor in tissue distribution.

The molecular format of single-molecule mixed agonists can theoretically take two designs: a fusion molecule where monoagonist analogs are appended together in a multivalent format, or a sequence-intermixed molecule of comparable size to the native peptides (Fig. 3). The latter is the preferred approach to date for GLP-1, GIP, and glucagon mixed agonists. These three receptor targets are all class B GPCRs, and the native ligands have a high degree of sequence similarity and secondary structure. Furthermore, each of these receptors has cross-reactivity to the other hormones, with GLP-1R appearing to be the most promiscuous of the receptors. Likewise, glucagon is the ligand that shows the most cross-reactive activity at the two incretin receptors. This pattern of activity, combined with the analogous ligand structure, provides the unique foundation and opportunity to build sequence-intermixed molecules. Notably, this is unlikely the case for the reported GLP-1 fusions to amylin or gastrin (112, 113). Sequence-intermixed unimolecular peptides have several advantages. First, when agonism is appropriately balanced, single peptides can only occupy one receptor at a time, unlike what could happen for multivalent fusions. Theoretically, this reduces the binding at any one receptor when delivered at equimolar concentrations, which may be of practical importance when trying to limit adverse side effects attributed to a particular receptor activity. As with all hybrids or fusions, there is a real concern of developing neutralizing antibodies to the drug itself, or worse, to the endogenous hormones. It is too early in the clinical progression of these molecules to estimate if one molecular format is preferred to limit these immunogenicity concerns.

Balanced vs preferential agonism

An important consideration in the design of multiagonist therapies is the relative potency of the compound at each of the cognate receptors. Compounds can be engineered either to be balanced in mixed agonism with equal potency at each of the targeted receptors, or the agonism ratio skewed in favor of one receptor over others (Fig. 3). This is an important consideration when trying to leverage maximal efficacy and potency vs unwanted dose-dependent side effects. This is particularly evident in mixed agonists in which one of the constituent activities is aimed at GCGGR. GCGR agonism is a vital component to drive body weight loss, but a steep dose response and the hyperglycemic liability must be compensated for by having appropriate incretin receptor activity. Identifying the optimum ratio to improve one metabolic endpoint, for instance body weight, may not be the same ratio that is optimum for other readouts, such as glucose or lipids. Furthermore, the optimum ratio identified in preclinical models of diabetes and obesity may not be the optimum ratio in human subjects. Moreover, the heterogeneity of these disease states in human patients complicates identifying the optimum ratio in clinical pharmacology experiments.

Another caveat is actually how to define the ratio of activity. To support high-throughput screening in structure–activity relationship (SAR) studies, oftentimes functional assays and binding assays are used to assess potency through the use of artificial cell systems in which a single receptor is overexpressed. To determine the relative potency of each constituent
within a single-molecule multiagonist, receptor expression should be controlled between the various assay systems so that cross-comparisons can be accurately assessed to relate the measured potencies against each other. However, this ignores the likelihood of differing levels of expression between these receptors at a whole-body level, as well as a tissue-specific pattern. Furthermore, the endogenous peptides have slightly different binding affinities for their native receptor, as well as measurable levels of cross-reactivity at the other related receptors. So defining the activity ratio at the constituent receptors must factor in these slight differences in inherent binding characteristics.

A common approach to protract time action is to promote binding to circulating albumin or other plasma proteins, most commonly through fatty acid acylation of the peptide. Therefore, when using in vitro assays to estimate an activity ratio, one must also consider the influence of albumin in bioassays, which is oftentimes included in low percentage to prevent compounds from sticking to assay plates. However, testing in the presence of albumin at concentrations that are consistent with circulating concentrations is another strategy to assess potency ratio in a condition that more closely resembles the in vivo situation. This in vitro approach essentially assesses the activity of the bound vs unbound fraction when testing in the presence or absence of albumin, and can be used as an in vitro tool to predict in vivo protraction. This should be used with caution though, as the type of fatty acylation and its placement on the backbone of the peptide can differentially influence the measured activity. All that being said, these strategies only take into account that a single receptor is expressed in a single cell. In other words, this does not take into account that receptor crosstalk can influence potency, which has been reported for this family of receptors (114).

Receptor preference is particularly important in tissues expressing multiple receptors. For example, GLP-1R/GIPR dual agonists were designed to optimize insulin secretion from the β cell while using less pressure on GLP-1R to mitigate the dose-limiting gastrointestinal side effects of GLP-1R agonists. To assess balanced agonism in cells coexpressing incretin receptors that converge on the same signaling pathways, such as β cells, various knockdown approaches such as viral-mediated, selective pharmacological inhibition or CRISPR/Cas9-mediated technology can be used (115). These technologies are important for high-throughput screening of candidate agonists, particularly because receptor agonism does not fully blunt receptor-mediated intracellular signaling. Use of these technologies will aid in developing appropriate agonism, particularly in cell types with overlapping receptor expression.

During the evaluation of single-molecule mixed agonists or fusions, it is important to demonstrate the multiple pharmacology within the molecule and to estimate the contribution of each component to the total efficacy. Although the use of genetically modified mice seems to be the preferred approach, genetic compensations can oftentimes substantially influence the physiology of these mice such that the

---

Figure 3. Design considerations of triagonists. (a) Each receptor (GLP-1R, blue; GCGR, red; GIPR, green) responds to its respective ligand. (b) A balanced fusion structure uses each individual peptide to provide recognition at all receptors. (c) A balanced hybrid peptide is a sequence-hybridized molecule of comparable size to the native peptides with equipotent activities at all receptors. (d) An unbalanced hybrid peptide is a sequence-intermixed molecule that preferentially activates certain receptors with higher affinity than others.
pharmacological assessment of mixed agonists in these mice can be complicated (116). Therefore, it is equally advantageous to make selective chemical knockouts where the activity of a single component of the multiagonist is reduced by a slight modification to the chemical structure. Rationally, this is easier to achieve in a single-molecule fusion, as the SAR of the single molecules can pinpoint the exact amino acids that can be mutated to inactivate a single component. This is more complicated to achieve with sequence-intermixed single molecules, but it can be done (28).

**Approaches to integrate activities at multiple receptors**

The unimolecular GLP-1/glucagon, GLP-1/GIP, and GLP-1/GIP/glucagon peptides have been designed using various precursor hormones as the scaffold in which residues from the other hormones were introduced into these peptide backbones to introduce mixed agonism. Those precursor scaffolds include glucagon, exendin-4, and oxyntomodulin. In general, the molecular design of these multiagonists starts with a thorough understanding of the SAR of the individual hormones, particularly those sites that are crucial for individual activity and those sites that are dispensable for binding and activity. Leveraging lessons from these understandings, the swap of crucial domains between the hormones can lead to the identification of single-site substitutions that are crucial for peptide–receptor interactions at each targeted receptor. Additional mutations can be introduced into the sequence to optimize the activity balance, chemical integrity, biophysical stability, and in vivo time action.

In an approach to generate GLP-1/GCGR dual agonists, glucagon was used as the scaffold to which residues specific to GLP-1 or exendin-4, notably select amino acids derived from the proximal C-terminal domain, were introduced to gain potency at GLP-1R (117). In a different iteration of this type of coagonist, oxyntomodulin, an endogenous coagonist of weak potency and imbalanced activity, was used as the scaffold. N-terminal and distal C-terminal modifications were introduced to improve potency and activity balance with the auxiliary function to improve in vivo time action (118). Coming from the other angle, exendin-4 has been used as the scaffold to which a glucagon-derived central domain was introduced to gain GCGR potency. N-terminal modifications derived from glucagon and C-terminal modifications derived from oxyntomodulin are required to achieve higher potency and balanced activity (119). Stabilization of the α-helical nature of the peptide, particularly within the mid-domain of the sequence, is a somewhat universal strategy to enhance potency across this broad class of ligands and receptors. This was achieved through covalent lactamation of the backbone (117, 120), introduction of alternately charged residues in a particular register to create a salt bridge (119), or introduction of an aminoisobutyric acid (Aib) residue, which has inherent helical-promoting properties (121). Interestingly, it has also been observed that fatty acid acylation, which typically is used to promote binding to plasma proteins or membrane anchoring to protract time action, can also contribute to the pharmacophore for promoting promiscuity at GLP-1 and glucagon receptors, likely by promoting specific secondary structure of the ligand (122).

Relative to GLP-1/glucagon coagonists, much less has been reported regarding the structural aspects of GLP-1/GIP coagonists. To build GLP-1/GIP receptor coagonists, a chimeric sequence of GLP-1 and exendin-4 was used as the scaffold to which GIP-specific residues were incorporated to introduce sufficient potency at GIPR (27). The N-terminal tyrosine derived from GIP, along with isoleucine at position 12 and lysine at position 16, were pivotal for gaining GIPR activity, whereas Aib residues at positions 2 and 20 also were instrumental in gaining substantial GIPR potency without compromising GLP-1R potency. Fatty acid acylation and polyethylene glycol (PEG)ylation of these peptides resulted in analogs sufficient for once-daily administration. To generate GLP-1/GIP/glucagon triagonists, respective coagonists were used as the scaffold to which alterations were made to introduce activity at the third receptor. Starting with the aforementioned GLP-1/GIP coagonist, simple mutation at the third position to glutamine rendered a balanced triagonist by in vitro measure (28). However, uncharacterized in vivo limitations with this backbone precluded its further pursuit. Alternatively, starting from the GLP-1/glucagon coagonist, inclusion of Aib at the second position, introduction of the C-terminal extension derived from exendin-4, site-specific acylation at position 10 of the backbone, and the selective inclusion of GIP-derived residues yielded a highly potent, and relatively balanced, triagonist (28). Multivalent fusions of GLP-1, GIP, and glucagon analogs have also been reported. In this molecular format, antibody domains were used to anchor all three constituents into a multifunctional antibody (123). The antibody fragment serves the ancillary function to protract time action as well.

**Performance of various dual agonists**

**GLP-1R/GCGR dual agonists**

Combination of GLP-1R agonists with GCGR agonists was founded in the idea that both agonists use complimentary mechanisms to induce weight loss, whereas GLP-1R activation would combat any negative effect of GCGR activation on glycemia. Ideally this treatment strategy would engage receptor agonism and subsequent weight-reducing activities in a broader range of tissues, as GCGR and GLP-1R are
nonoverlapping in many cell types. This is supported by findings from human confusion studies, where glucagon and GLP-1 maintained their individual effects on energy expenditure and glycemia, respectively, when infused in combination (124). Although GLP-1 and glucagon both exert similar actions at the β cell for insulin secretion, their nonoverlapping functions at other tissues are the primary benefit for their combination in treatments. Glucagon adds adipose tissue lipolysis and appetite suppression and elevates energy expenditure to the known GLP-1R agonist actions on glycemia and weight reduction. The concept for developing this dual-agonist pair is aligned with studies of the proglucagon-derived peptide oxyntomodulin. Oxyntomodulin exerts its antidiabetic effects through binding at both the GLP-1R and GCGR; it reduces glycemia through the GLP-1R while stimulating weight loss through increased energy expenditure by activation of GCGR (125). However, oxyntomodulin is not as potent an activator of GLP-1 and GCGR as either of their cognate ligands, having 10- to 100-fold less activity at the receptors than their respective ligands (126). Additionally, oxyntomodulin, like GLP-1, is a substrate of DPP4, and as such is labile in vivo, exhibiting a half-life of ~12 minutes (127). Another study used a dual agonist similar to oxyntomodulin, but with cholesterol added to a Cys side chain near the C-terminal that allowed for enhanced duration of action (118). In the same study, this group compared an agonist with a single residue change that no longer exhibited any activity at the GCGR to analyze the benefits of compounding GCGR activation onto GLP-1R activation. Dual agonism significantly reduced body weight compared with vehicle or GLP-1R activation alone. The dual agonist yielded similar effects on food intake compared with GLP-1R agonism alone, suggesting that GCGR agonism has complementary actions to GLP-1R agonism for weight reduction. Activities at both receptors were confirmed using Glp1r−/− and Gcgr−/− mice. An important finding was that compared with GLP-1R agonism alone, there was no significant difference on glucose tolerance for the combination with GCGR agonism. Thus, glucagon receptor agonism is successfully balanced by the activation of the GLP-1R. These studies provided the impetus to develop more potent dual activators of GLP-1R and GCGR for more effective weight loss and glycemic improvements.

The combination of GLP-1 and glucagon has been thoroughly proven as an effective weight loss strategy. For example, acute administration of subanorectic doses of individual peptides (GLP-1 at 0.4 pmol/kg/min and glucagon at 2.8 pmol/kg/min) to nondiabetic, overweight patients yielded reduced food intake and increased satiety compared with either peptide alone (128). Notably, this occurred in the absence of nausea, demonstrating the potential for increasing weight loss with diminished adverse side effects from increasing the dose of GLP-1R agonists. In this study, neutral results were observed for glycemia, whereas glucagon infusion alone elevated glycemia. This suggests that higher doses of glucagon may be more effective than low doses, as glucagon could exert its effect at the β-cell GLP-1R at higher circulating levels, compared with low levels where glucagon’s effect on hepatic glucose output may prevail. Based on the superior outcomes of combination therapy for weight loss, several groups developed coagonist therapies. Development of these stable coagonists have allowed for better understanding of glucagon biology, as glucagon is rapidly degraded, and therefore, primarily acute activities of glucagon have been reported. One group generated a balanced 40-kDa polyethylene glycol (PEG)ylated coagonist peptide for once-weekly administration (117). This compound, Aib2 C24 lactam 40k, when administered subcutaneously at a high dose, reduced body weight in a mouse DIO model by 25.8% in 1 week as a result of reduced food intake and decreased fat mass. In the longer term, low-dose studies demonstrated comparable weight loss to the short-term administration of high doses, but weight loss was associated with increased energy expenditure and thermogenesis, with no differences observed in caloric intake or locomotor activity. The balanced coagonist also demonstrated benefits for lipid metabolism, leading to reduced cholesterol levels and subsequent reduction of hepatic steatosis. Notably, this balanced agonist compound outperformed preferential agonists and maintained its weight-lowering activity in mice lacking the GLP-1R, demonstrating the utility of glucagon-directed strategies. In a study assessing balanced vs unbalanced agonism, GCGR agonism was efficacious at lowering weight loss, but was most effective when paired with appropriate GLP-1R agonism to mitigate effects on glycemia (129). Thus, balance of receptor agonism, as determined using in vitro systems to evaluate respective activities, should be considered to maximize weight loss while considering hyperglycemic risks that are associated with glucagon action on hepatic glucose output.

Several compounds have been clinically pursued in this class of drug candidates. The earliest was LY2944876 or TT-401, created by Transition Therapeutics in collaboration with Eli Lilly. This compound was an oxyntomodulin analog that was formulated for weekly administration, and imbalanced in activity, in favor of GLP-1R activity relative to GCGR activity. At the highest dose, 50 mg, HbA1c was decreased by 1.4% and body weight reduced by 3.3 kg after 24 weeks of administration (130). However, LY2944876/Tt-401 has not been continued into phase 3 trials, but is being reassessed by OPKO Health, Inc. Sanofi has also developed a dual-agonist compound, SAR425899, which has ongoing phase 2 clinical trials. SAR425899 is formulated for daily administration, and preliminary results have shown that at the highest dose, a 5.5-kg
reduction in body weight was observed with a modest reduction in HbA1c after 4 weeks of treatment (131). This compound is also imbalanced in relative activity with higher GLP-1R potency. Despite positive preliminary results from the phase 2 proof-of-concept studies, gastrointestinal tolerability issues prevented the continuation of the study, which was likely the result of the dose escalation schedule. Another compound, MED10382, developed by MedImmune and AstraZeneca, demonstrated robust efficacy in rodent and cynomolgus monkey models for weight loss and glucose control when administered in comparable doses to liraglutide (132) and is now in phase 2b trials. Several other companies have dual agonists in the pipeline, including Janssen with Hanmi Pharmaceuticals (HM12525A/JNJ-64565111; phase 1), Zealand Pharma (ZP2929/BI 456906; phase 1), Merck (MK-8521; phase 2), and Novo Nordisk (NN9277; phase 1) (133).

**GLP-1R/GIPR dual agonists**

The pursuit of GLP-1R/GIPR dual agonists lagged behind the development of GLP-1/glucagon agonists, largely due to the limitations of using GIP, as discussed above. Conceivably, these dual agonists would exert their activities in two steps. First, GLP-1R agonism would elicit glycemic control, among its effects on body weight, allowing GIPR sensitivity, and thus secondary modulation of glycemia and body weight by GIP. This strategy is supported by the finding that in diabetic patients, who are unresponsive to GIP alone, there was additive, increased first-phase insulin secretion in response to coinfusion of GLP-1 and GIP at physiologic levels (134). However, several additional acute human coinfusion studies found no further benefit of GIP addition to GLP-1 infusion (135–137). Thus, the effect of long-term administration of GIP, when added to GLP-1, could not be inferred from these patient studies. As such, when compared with equimolar doses of either incretin alone, the combination of GLP-1 and GIP in a rodent model of DIO was more efficacious at reducing body weight, food intake, and adiposity (27). No additive or synergistic effect of the incretin combination was observed for lowering glycemia in nondiabetic rodents, suggesting redundancy of action at the level of GPCR-mediated potentiation of insulin secretion in β cells. Notably, GIPR agonism alone had no effect on fat mass or body weight yet when combined with GLP-1R agonists was able to outperform GLP-1R agonism alone. These findings provided the rationale to develop a balanced, unimolecular dual-agonist peptide for the treatment of metabolic syndrome and T2D (27). The acylated GLP-1R/GIPR dual agonist, which had an optimal pharmacokinetic profile to decrease dosing frequency to once daily, outperformed liraglutide in a mouse DIO model in all parameters tested; at the highest dose (equivalent to the tested dose of liraglutide), the coagonist more potently reduced body weight, food intake, fat mass, and blood glucose by 1 week post-treatment initiation. These effects persisted with biweekly injections in DIO mice and, in fact, amplified after 30 days with the added benefit of significantly lowered total cholesterol levels compared with liraglutide. Notably, the coagonist was able to reduce weight gain independent of an effect on energy expenditure or locomotion, and was not solely due to decreased food intake, as pair-fed mice did not lose body weight at the same magnitude as coagonist-treated mice. This finding demonstrates unique synergistic effects of incretins when dosed together that have yet to be described. Though fatty acid–acylated and PEGylated versions of the coagonist were developed, the former compound outperformed the latter compound for lowering body weight, while performing similarly for all other metabolic endpoints tested. Comparable findings were observed across several models, including db/db mice and cynomolgus monkeys. Importantly, this compound reduced the gastrointestinal side effects associated with monoaigonism of GLP-1R.

Further supporting the concept of dual-incretin agonism, coadministration of fatty acid–acylated analogs of GLP-1 and GIP improved body weight and hyperglycemia in metabolically compromised mice (138). Additionally, Zealand Pharma recently developed a unique GIP analog, ZP4165, which in physical combination potentiated the effects of liraglutide (139). ZP4165 is more stable than native GIP, allowing for long-term assessment of GIPR activation alone in the db/db model of T2D. This GIP analog was stabilized through multiple modifications that include position 2 Aib to prevent DPP4 degradation, and a C16 fatty acid was added to Lys17 to increase the peptide half-life by increasing albumin binding. Twice-daily injections of ZP4165 reduced glycemia and increased insulin secretion in a DIO mouse and db/db model of T2D. Interestingly, when ZP4165 was coadministered with liraglutide, the profile observed was similar to that previously observed with the unimolecular dual agonist (27), demonstrating synergistic lowering of HbA1c and body weight. Combination treatment of the two incretin receptor agonists also corroborated the effects of dual agonism on total cholesterol, as lowering was only observed when GLP-1R and GIPR were both activated, with no change observed with either treatment alone.

GLP-1/GIP coagonism has recently demonstrated benefits in models of Alzheimer’s and Parkinson disease. Alzheimer’s disease increases the risk of developing T2D, and both Alzheimer’s and Parkinson diseases are associated with insulin resistance and inflammation (140, 141). The fatty acid–acylated dual GLP-1R/GIPR agonist described above has recently been tested in animal models of Alzheimer’s and Parkinson disease, as well as traumatic brain injury (142). The coagonist demonstrated decreased brain
inflammation, insulin resensitization, and reduced cognitive impairment in an Alzheimer’s mouse model using intracerebroventricular streptozotocin, a Parkinson mouse model using 6-hydroxydopamine lesion, and a Parkinson mouse model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (143–145). Though not all of these studies performed direct comparisons to GLP-1R or GIPR monoagonists, promoting either GLP-1 or GIP signaling alone has yielded benefits for cognitive impairment in either clinical or preclinical studies of Alzheimer’s and Parkinson disease, suggesting the potential for additive or synergistic benefits of dual agonists (146–151). Further studies are necessary to determine the full array of benefits from multireceptor agonism in the brain.

Although the results from the studies mentioned above are from preclinical studies, the clinical effects of a dual GLP-1R/GIP receptor agonist developed by Novo Nordisk, NNC0090-2746, have recently been described from phase 2a trials (152). NNC0090-2746, previously called RG7697, is the balanced, unimolecular, fatty acid–acylated GLP-1R/GIPR agonist that has been tested in several preclinical models and safety verified in patients (27). NNC0090-2746 is thought to bind only one receptor at a time, and this concept guided the dosing in clinical trials: the study based dosing on high doses of liraglutide with the expectation that gastrointestinal side effects would be curbed due to decreased GLP-1R occupancy. In phase 1 studies, NNC0090-2746 displayed similar adverse effects as GLP-1R agonists, only at the highest doses (153, 154). NNC0090-2746 was found to reach steady-state levels in patients after daily dosing for 1 week during phase 1 studies. In the recently described phase 2a studies, the dual-agonist compound was administered to 37 patients once daily for 12 weeks, with HbA1c as the primary endpoint (152). Dual GLP-1R/GIPR agonism was highly efficacious, significantly reducing HbA1c by 0.96% and fasting plasma glucose by 38.2% after 12 weeks of dosing when compared with placebo. Body weight was significantly reduced by 1.8% after 8 weeks of dosing, and, although not statistically significant, a similar absolute reduction was observed after 12 weeks of treatment. Total cholesterol was 8% lower than that observed in the placebo group, whereas liraglutide alone had no effect, suggesting a potential benefit of dual-incretin use that requires further investigation. Despite the clear efficacy of NNC0090-2746, insulin sensitivity could not be established, and will need to be further studied in larger scale trials.

It is important to note that all combination therapies demonstrate beneficial effects of GIP, particularly when coupled with GLP-1R agonism. This is counter to early genetic studies that suggested loss of GIPR signaling was protective for DIO (51, 58). Taken together, the data from multireceptor agonist studies utilizing GIPR engagement supports further development of GIP agonists as a viable aspect of a comprehensive treatment strategy for T2D. Certainly, GIPR agonism in the presence of GLP-1R agonism demonstrates consistent, synergistic effects on targets of obesity and T2D and, as such, supports its incorporation into triagonist therapies, as will be discussed in the following section.

**Effects of GLP-1R/GIPR/GCGR triagonism**

GLP-1R, GIPR, and GCGR triagonism is supported by findings from successful dual agonists and clinically effective monoagonists. Conceptually, its use is founded in a three-prong approach: GLP-1R agonism supports weight loss and insulin secretion, GCGR agonism activates independent, complimentary weight loss mechanisms, and GIPR agonism further buffers glucagon-mediated hepatic glucose production via amplified potentiation of insulin secretion. Balanced triagonists are similar in length to endogenous glucagon and are about as close in sequence as exendin-4 to GLP-1 (24).

An early triagonist approach was the development of a hybrid GIP-oxyntomodulin hybrid peptide, DA1GIP-Oxm. DA2GIP-Oxm was developed by replacing the first 11 residues from the N-terminal of oxyntomodulin with D-Ala-GIP (155). Thus, this peptide was resistant to DPP4 degradation and effective at stimulating cAMP through GIPR, GLP-1R, and GCGR. Although this unimolecular peptide was effective, it was less potent at each receptor (GIPR, GLP-1R, and GCGR) compared with the respective native ligand. DA1GIP-Oxm more potently reduced glycaemia and decreased body weight compared with any individual peptide; however, it is important to note that comparison with the clinical standard, liraglutide, was not performed and, based on percentage weight loss, would have performed similarly.

Other triagonists were developed utilizing the peptide sequence of the three endogenous peptides. First, [dA2]GLP-1/glucagon was identified as the most promising candidate from iterative changes of peptide sequences containing components of each incretin/glucagon peptide to form several hybrid peptide candidates (156). [dA3]GLP-1/glucagon was administered twice daily for 3 weeks and demonstrated significant decreases in body weight and glucose, with concomitant elevation in plasma insulin. This peptide also performed similarly to exendin-4 in glucose tolerance tests and had similar potency for cAMP stimulation in receptor transfected cells. Another agonist was developed by manipulating the native glucagon sequence and termed Y1-dA3-I12-N17-V18, I12-G28,29-glucagon (157). Although this peptide did use all three receptors to elicit its maximal response, it was less potent than any native peptide for its cognate receptor. Twice-daily administration had no effect on body weight, but significantly improved glycaemia in high-fat-fed mice (157). Notably, this study did not
compare with effective monoagonist or dual-agonist strategies, so the relative effectiveness of this strategy could not be assessed. However, this was the only multireceptor-agonist strategy that had no effect on body weight, suggesting unbalanced agonism, as monoagonism of the GLP-1R or GGGR consistently elicits weight loss. Both [dA\textsubscript{13}-V\textsubscript{12}-G\textsubscript{20}-V\textsubscript{18}-dA\textsubscript{13}-N\textsubscript{15}-V\textsubscript{18}-dA\textsubscript{13}-G\textsubscript{20}]glucagon displayed an apparent lack of synergism, indicative of unbalanced agonism and submaximal potency.

A highly effective, balanced triagonist structure was published by Finan et al. (28) in 2015. The triagonist sequence was developed from iterative residue changes that yielded a sequence-intermixed peptide with multireceptor activity. This peptide was resistant to DPP\textsubscript{4} cleavage, and thus exhibits an extended half-life, similar to liraglutide. The resultant triagonist was at least as potent as the native peptide at each respective rodent and human receptor. When administered at equimolar concentrations against a proven incretin dual agonist, the triagonist decreased body weight of DIO mice by 26.6% in 20 days, outperforming the dual-incretin receptor agonist by 9.9%. This enhanced weight loss occurred independent of food intake, gastric emptying, or changes in lean mass compared with the dual-incretin receptor agonist, suggesting no adverse effect of glucagon receptor agonism in this peptide. The triagonist offered additional benefits for lipid metabolism; the triagonist significantly reduced plasma cholesterol and reduced markers of hepatic steatosis. Most preclinical studies validate their compounds in male mice because female mice are relatively resistant to DIO and maintain normal glucose tolerance. Thus, this triagonist was recently tested in both age-matched and weight-matched female mice to validate its effects independent of sex (158). The triagonist performed similarly in both male and female mice, further supporting its translation to the clinic for treatment of obesity and T2D. Of the tested triple-agonist compounds developed, this GLP-1/GIP/glucagon triagonist compound was the most efficacious, likely due to its balanced receptor agonism and superior potency to native peptides at their cognate receptor. Notably, proper balance of the triagonist in regards to glucagon was important to achieve the full weight loss benefits of triagonism. Currently the triagonist compound, MAR\textsubscript{423}, developed by Novo Nordisk, is in early clinical trials (133).

A unique long-acting triagonist, HM\textsubscript{15211}, was recently described by Hanmi Pharmaceuticals in preclinical models of T2D, nonalcoholic steatohepatitis (NASH), and Parkinson disease (159, 160). HM\textsubscript{15211} significantly outperformed liraglutide for decreasing body weight, reducing hyperglycemia, and increasing energy expenditure (160). This efficacy was observed with administration every other day compared with twice-daily liraglutide administration. Similar body weight loss was observed with weekly administration. HM\textsubscript{15211} significantly lowered blood cholesterol and hepatic steatosis in high-sucrose-fed rats and methionine choline-deficient mice, two models of NASH (160). Additionally, HM\textsubscript{15211} protected against MPTP-induced Parkinson disease in mice by attenuating microglial activation and inflammation in the striatum and substantia nigra (159).

Based on the broad beneficial effects of HM\textsubscript{15211}, it is currently being tested in phase 1 clinical trials for obesity and NASH.

**Summary and Perspectives**

Multireceptor agonists have shown improvements over monoagonist strategies for the treatment of T2D, obesity, and several associated complications. It is clear that agonism of all three receptors work in concert to increase insulin secretion, while reducing adiposity through decreased food intake and elevated energy expenditure. However, based on the significant effects across various tissues, there is room for the exploration of these multireceptor agonists for a broad range of diseases. For example, triagonists may be efficacious at reducing obesity, even in the absence of T2D. Furthermore, several triagonist compounds have already demonstrated cholesterol-lowering effects and benefits for nonalcoholic fatty liver disease (28, 158, 160). Moreover, although the mechanisms are not well defined, these multireceptor agonists may be efficacious for slowing the progression of neurologic diseases associated with T2D, such as Parkinson disease (140, 161). The broad benefits of multireceptor agonism should be considered in future designs of preclinical studies and clinical trials.

Despite the pursuit of several multireceptor agonists in the clinic, a question still remains regarding the molecular mechanisms underlying synergism. One potential explanation of the results is that the triagonists are just more potent activators of GLP-1R, and thus the benefits are due to increasing activity of the single receptor. However, this is unlikely the case, as the most effective multireceptor agonists have balanced activity across the three receptors. Moreover, GLP-1R agonists are currently used at submaximal doses due to gastrointestinal issues, and therefore if the multitagonist receptor was merely more effective at the single receptor, it would be expected to not be well tolerated in patients. Currently, the intracellular signaling mechanisms of multireceptor agonism are unclear. In the case of GLP-1 and GIP, GLP-1 activity removes the brakes on GIP activity found in T2D. This is supported by findings that lowering glycemia restores GIP action on insulin secretion. Thus, in terms of insulin secretion, GLP-1 and GIP may act on their cognate receptors to increase insulin secretion more than either individual peptide can achieve. This may explain the results observed with the unmolecular
dual-incretin agonist, where a plateau in the effect of GLP-1R monoagonism was surpassed by the addition of GIP (27). Another potential explanation for synergism is that lateral intracellular interactions occur, in which downstream-signaling intermediates allosterically modify coincident signaling pathways within the same cell. Further work is necessary to understand the molecular basis of synergism to maximally harness its benefits as therapies for T2D.

With the advent of single-cell transcriptomics, it will be necessary to understand coexpression profiles of receptors within the same tissues. For instance, it has been postulated that unique subpopulations of β cells exist and, potentially, GLP-1R, GCGR, and GIPR exist on unique populations of cells. Thus, the additive benefits of multireceptor agonism may result from the engagement of multiple cell populations that have unique receptor expression (Fig. 4a). Understanding expression profiles within a single cell will provide insights into the complexity and heterogeneity that might exist in various target tissues. Conversely, if receptors are expressed on the same cell, engagement of multiple receptors simultaneously may confer the benefits of multiaagonists (Fig. 4b). Whether synergism is the result of activating a broader network of cells, convergence of intracellular signaling, or a combination of the two has yet to be identified. The growing technology for single-cell genomics provides the ability to ask these questions with previously unattainable precision.

Neither GIP monoagonists nor antagonists have been validated clinically, but the lack of clinical investigation is largely predicated on studies using incomplete or inadequate tools to query GIP’s physiologic functions. A byproduct of GIP’s use in conjunction with GLP-1 is a better, albeit incomplete, understanding of its potential as a therapeutic. Several dual-incretin studies verified the action of their peptide’s activity at both receptors by using single-incretin receptor knockout mice. There were no reports of adverse effects on body weight or glucagon levels when dual-incretin peptides were administered to Gipr⁻/⁻ mice, suggesting safety of GIP administration alone. Furthermore, the use of these coagonists in models of neurologic disease demonstrates untapped therapeutic benefits of GIP agonism that have not been explored in relation to the central deficits associated with T2D. Additionally, the advent of specific GIPR antagonists or GIP-blocking antibodies has allowed for unique lines of investigation to query the endogenous actions of GIP, without the confounding factors associated with genetic manipulations. As such, development of stable GIPR agonists to fully understand its role remains a burgeoning area for drug development.

The incorporation of glucagon into multiaagonists aimed at treating T2D patients was initially controversial because of the hyperglycemic liability, but opinion has largely changed and is supported by its effects on energy expenditure and lipolysis. Glucagon stimulates hepatic glucose output, and as such glucagon receptor agonism had not been pursued. Even the current success of coagonists utilizing glucagon biology solely focuses on the GLP-1-independent central benefits of glucagon on energy expenditure and thermogenesis. However, there are likely unappreciated roles that contribute to glucagon’s efficacy. Most notable, glucagon is a

**Figure 4.** Two hypothesized models of synergism for β-cell insulin secretion. (a) According to the cell heterogeneity model, unique populations of β cells exist that do not express all three incretin/glucagon receptors. In this model, the triagonist increases insulin secretion compared with a monoagonist by engaging multiple β-cell subgroups to stimulate insulin secretion. (b) In the intracellular amplification model, β cells express all incretin/glucagon receptors, and the synergistic activity of the triagonist compared with the monoagonist is based on the crosstalk of downstream signaling cascades within an individual β cell.
potent insulin secretagogue. One hypothesis for the primary physiologic role of glucagon is that it functions to maintain normal levels of amino acids, and its glycemic effects are a byproduct of amino acid metabolism (162). During hypoglycemia, amino acids are synthesized from muscle and fat, stimulating glucagon and promoting hepatic glucose production. Conversely, when glycemia is elevated, such as in overnutrition or in response to a protein-rich meal, elevated amino acids stimulate glucagon and in turn glucagon elevates insulin secretion in a paracrine manner. The largely beneficial effects of glucagon incorporation into unimolecular peptide agonist strategies support the notion that glucagon may have beneficial effects beyond its stimulation of GCGGR in the brain.

Taken together, the similar peptide sequences of GLP-1, GIP, and glucagon, coupled with their diverging activities in a broad range of target tissues, position triagonists as a unique drug class that could recaptivate the vast benefits of bariatric surgery for T2D. Although monagonism of GLP-1R has yielded important benefits for weight management and glucose control clinically, the potential for triagonism could vastly improve clinical outcomes for T2D patients, beyond what is even purported for dual-receptor agonists. Triagonism offers the benefit of substantial weight loss from glucagon action, with reduced hyperglycemic risk from the addition of GIP action in addition to the reported actions of GLP-1. Yet in a broader context, the synergistic effects observed by multireceptor agonists have provided new lines of inquiry for understanding incretin/glucagon biology, which opens the possibility for further optimization and translation of therapies into the clinic in the future.

References

1. Bommer C, Heesemann E, Sagalova V, Mann-Goehler J, Atun R, Bärnhäuser T, Vollmer S. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423–430.
2. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.
3. Nauck MA, Homberger E, Segel EG, Allen RC, Eaton RP, Næveller R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492–498.
4. Pearson MJ, Unger RH, Holland WL. Clinical trials, triumphs, and tribulations of glucagon receptor antagonists. Diabetes Care. 2016;33(7):1075–1077.
5. Muller TD, Finan B, Clemmensen C, DiMarchi RD. Tschöp MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(3):721–766.
6. Meek CL, Lewis HB, Remann F, Gribble FM, Park AJ. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides. 2016;77:28–37.
7. Nannipieri M, Baldi S, Mari A, Cuglioni D, Guarino D, Camassia S, Borsotti E, Berta R, Moncorodi B, Bellini R, Anselmino M, Ferrarini E. Roux-en-Y gastric bypass and sleeve gastroectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98(11):4391–4399.
8. Laferrère B, Heshka S, Wang K, Khan Y, McCoy J, Teixeira J, Hart AL, Olivan B. Incretin levels and effects are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30(7):1709–1716.
9. Laferrère B. Bariatric surgery and obesity influence on the incretins. Int J Obes Suppl. 2016;41(Suppl 1):S32–S36.
10. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992–1019.
11. Hanssotia T, Baggio LL, Delmère D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holtz JJ, Schuit F, Drucker DJ. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enterosplanar axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes. 2004;53(5):1326–1335.
12. Mano SP, Danels GL, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poultier NR, Ravn LS, Steenbjerg WM, Stockner M, Zinman B, Bergensdal RM, Buse JB, Committee LS, Investigators LT, LEADER. Screening Committee-LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(1):31–32.
13. Jia X, Alam M, Ye Y, Bajaj M, Birnbaum Y. GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials. Cardiovasc Drugs Ther. 2018;32(1):165–72.
14. Mano SP, Bain SC, Consoli A, Elashewitz FG, Jódar E, Leier LA, Linglay I, Rosenstock J, Seudert J, Warren ML, Wao V, Hansen O, Holtz AG, Pettersson J, Vildhab T, Investigators S, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
15. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavsson SM, Iqbal N, Maggioni AP, Mano SP, Öhman P, Pagidipati NJ, Poultier N, Ramachandran A, Zinman B, Hernandez AF, Group ES, EXCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(5):950–957.
16. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Feinberg J, Flanigan T, Harrington RA, Holmes J, Judson D, Krum H, Lopes VF, Solomon SD, Tardif JC, Investigators E, EUA Investigators. Lixisenatide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2013;368(12):1228–1239.
17. Trock RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis. 2014;5(1):1–14.
18. Evers SS, Sandoval DA, Seeley RJ. The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. Annu Rev Physiol. 2017;79(1):313–334.
19. Wilson-Pérez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, Stoffers D, Drucker DJ, Pérez-Tilve D, Seeley RJ. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes. 2013;62(7):2380–2385.
20. Ramachaney RD, McCulloch LJ, Clark A, Wiggins D, Johannessen H, Olsen MK, Cai X, Zhao CM, Chen D, Ronnans P. PYY-dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following Roux-en-Y gastric bypass surgery. Cell Reports. 2016;15(5):944–950.
21. Caribay D, McGavigan AK, Lee SA, Ficorilli JV, Cox AL, Michael MD, Sloop KW, Cummings FP. β-Cell glucagon-like peptide-1 receptor contributes to improved glucose tolerance after vertical sleeve gastrectomy. Endocrinology. 2016;157(7):3405–3409.
22. Ryan KK, Temraoui V, Clemmensen C, Kovatcheva-Datchary P, Myronovich A, Kars N, Wilson-Pérez HE, Sandoval DA, Kohli R, Bächler F, Seeley RJ. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7500):183–188.
23. Hodge RJ, Nunez DJ. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype? Diabetes Obes Metab. 2016;18(5):439–443.
24. Tschöp M, DiMarchi R. Single-molecule combinatorial therapies for treating obesity and diabetes. Diabetologia. 2017;60(7):1766–1769.
25. Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol. 2012;8(1):425–433.
26. Tschöp MH, Finan B, Clemmensen C, Gelfand V, Perez-Tilve D, Müller TD, DiMarchi RD. Unimolecular polypeptide pharmacology for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51–62.
27. Finan B, Ma T, Ottaway N, Müller TD, Babekker GM, Hepper KM, Kirchner H, Holland J, Hambree J, Raver C, Lockie SH, Smiley DI, Gelfanov V, Yang B, Hofmann S, Bruegger D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gadda J, Vignati L, Zhang L, Hautman JB, Lau M, Brechenmacher M, Uhles S, Riboulet W, Hairatn E, Sebekova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschöp MH. Unimolecular dual
re-esertification in subcutaneous abdominal adipose tissue in lean humans. Diabetes. 2010;59(9): 2160–2165.

68. Gasberg JS, Cabe MBN, Hirtmann B, Christensen MB, Knop FK, Holst JJ, Rosenkilde MM. Glucagon-like peptide-1 (GLP-1) receptor antagonists as anti-diabetic agents. Peptides. 2018;100:173–181.

69. Asmar M, Asmar A, Simonsen L, Gasberg LS, Sparre-Ulrich AH, Rosenkilde MM, Hirtmann B, Dela F, Holst JJ, Bølow J. The glucose- and lip-oxidatory and vaso-protective effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor. Diabetes. 2017;66(9):2363–2371.

70. Kim SJ, Nian C, McIntosh CH. Activation of Ipo- protein lipase by glucagon-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem. 2007;282(12):8557–8567.

71. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase expression in adipocytes. J Biol Chem. 2007;282(14):13447–13457.

72. Mehran AE, Templeman NM, Brigidi GS, Lim GE, Capozzi et al. Incretin/Glucagon Triagonists for T2D Treatment. Endocrine Reviews, October 2018, 39(5):719–736.

73. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Yang J, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Lrough LA, Igl W, Iribarren C, Isomaa B, Jacobs KB, Jarick I, Jewell E, Asmar M, Asmar A, Simonsen L, Gasbjerg LS, Kieffer TJ, Bajmi SX, Clee SM, Johnson JD. Hyperinsulinaemia drives diet-induced obesity independently of brain insulin production. Cell Metab. 2012(6):723–737.

74. Ugelhoff, R, Pedersen J, Basri MR, Fütterer M, Jørgensen SM, Kissow HL, Nytofte N, Poulsen SS, Rosenkilde MM, Seino Y, Thams P, Holst JJ, Holst JJ, Haura M, Collins FS. 2010; 58(3):109–115.

75. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Yang J, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Lrough LA, Igl W, Iribarren C, Isomaa B, Jacobs KB, Jarick I, Jewell E, Asmar M, Asmar A, Simonsen L, Gasbjerg LS, Kieffer TJ, Bajmi SX, Clee SM, Johnson JD. Hyperinsulinaemia drives diet-induced obesity independently of brain insulin production. Cell Metab. 2012(6):723–737.

76. Speliotes EK, Willer CJ, Basri MR, Fütterer M, Jørgensen SM, Kissow HL, Nytofte N, Poulsen SS, Rosenkilde MM, Seino Y, Thams P, Holst JJ, Holst JJ, Haura M, Collins FS. 2010; 58(3):109–115.
94. Lee YH, Wang MY, Yu XX, Unger RH. Glucagon is the key factor in the development of diabetes. Diabetes. 2016;65(7):1372–1375.

95. Wang MY, Yan H, Shi Z, Evans MR, Yu X, Lee Y, Chiu YT, Wang J, Philipps R, Robb MG. Unger RH Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci USA. 2015;112(2):2503–2508.

96. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin deficiency type 1 diabetes in mice. Diabetes. 2013;62(3):391–397.

97. Kazerod DJ, Bergman A, Tan B, Erion DM, Somayaji V, Lee DS, Rolph T. Effects of multiple ascending doses of the glucagon receptor antagonist PG-06291874 in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(3):795–802.

98. Kadza CM, Ding Y, Kelly RP, Garbyan P, Shi C, Lim CN, Fu H, Watson DE, Levin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes 12- and 24-week phase 2 studies. Diabetes Care. 2015;38(12):2241–2247.

99. Muller WA, Falloona GR, Unger RH. The influence of the antecedent diet upon glucagon and insulin secretion. N Engl J Med. 1971;285(26):1450–1454.

100. Langhans W, Zeiger U, Scharrer E, Geary N. Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Science. 1965;148(3657):894–896.

101. Saltner JM, Ezrin C, Laidualj GC, Gornall AG. Metabolic effects of glucagon in human subjects. Metabolism. 1960;9(7):753–768.

102. Doi K, Kuroshima A. Modified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats. Life Sci. 1983;30(19):785–791.

103. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab. 1987;64(4):996–1001.

104. Hallback GM, Stemmer K, Cheng C, Møller KN, Naver L, Hvolris L, Clausen TR, Wulff BS, De Silva A, Viardot A, Alsafi A, Frost GS, Chatte MA, Bloom SR. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2016;65(4):1131–1138.

105. Poci A. Action and therapeutic potential of oxyntomodulin. Mol Med. 2013;19(3):241–251.

106. Baldissara FC, Holst J, Knutshes E, Hilsted L, Nielsen CV. Oxyntomodulin (glucorelin (33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept. 1988;21(1-2):151–166.

107. Zhu L, Tamvakopoulos C, Xie D, Dragicov J, Shen X, Fenyk-Melody J, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R. The role of dipoxydiphenylamide IV-III in the regulation of glucagon family peptides. in vivo metabolism of pituitary adenylate cyclase activating peptide(1-38) J. Biol Chem. 2003;278(25):22418–22423.

108. Cegla J, Troke RC, Jones B, Tharakan G, Kenjke J, McCullough KA, Lim CT, Parviz N, Huxsen M, Chambers ES, Minnion J, Chate MA, Meeran K, Tan TM, Bloom SR. Confirmation of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes. 2014;63(11):3711–3720.

109. Day JW, Gellfanov V, Smiley D, Carrington PE, Eiermann G, Cicchi G, Erion MG. Effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats. Peptides. 2015;69:1–75.

110. Roed SN, Nahr AC, Wissmann P, Iversen H, Brauner-Ohse KS, Knudsen SM, Walrhoel M. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking. J Biol Chem. 2010;285(2):1233–1243.

111. Naylor J, Suckow AT, Seth A, Baker DJ, Serendijas I, Ravn P, Howes R, Li S, Snaith MR, Coghlan MP, Horning DP. Use of CRISPR/Cas9-engineered INS1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists. Biochem J. 2016;473(18):2881–2891.

112. Ali S, Lamont BJ, Charron MJ, Drucker DJ. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the in cretin axis. J Clin Invest. 2011;121(5):1917–1929.

113. Day JW, Ottaway N, Patterson JT, Gellfanov V, Smiley DJ, Cidding J, Findeski MM, Brummer DJ, Drucker DJ, Chaudhary N, Holland J, Jemmerson M, Apbalvaro W, Grant E, Ruelh J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, McMarchi R, Tschop M. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–757.

114. Poci A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zang X, Sountis MM, Samportotes A, Capito E, Chiocci GC, Thornberry NA, Biachchi E, Pesa A, Marsh DJ, SinhaRoy R. Glucagon-like peptide-1 glucagon receptor dual agonists correct obesity in mice. Diabetes. 2009;58(10):2528–2566.

115. Evers A, Haack T, Lorenz M, Bossart M, Elvert R, Bergmann K, Keil S, Rimblaut M, Larsen P, Lorenz M. Safety, pharmacokinetics, and pharmacodynamics of the novel dual GLP-1/1glucagon agonist SAR425899 in healthy subjects and diabetes patients. 76th Scientific Sessions American Diabetes Association; June 10, 2017; San Diego, CA.

116. Tilker J, Posch MG, Hueser A, Teichert L, Eirig C, Bergmann K, Keil S, Rimblaut M, Larsen P, Lorenz M. Safety, pharmacokinetics, and pharmacodynamics of the novel dual GLP-1/glucagon agonist SAR425899 in healthy subjects and diabetes patients. 76th Scientific Sessions American Diabetes Association; June 10, 2016; New Orleans, LA.

117. Henderson SJ, Konkar A, Horning DC, Trevaskis JL, Jackson R, Fritsch Fredin A, Jansson-Löfmark R, Naylor J, Ross A, Bednarek MA, Bhagoe N, Sales H, Will S, Oldham S, Hansen G, Fehg M, Klein T, Grimby J, Maguire S, Jerrutus L, Rondinoni CM, Coghlan MP. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Metab. 2018;44(12):1176–1190.

118. Brandt SJ, Götz A, Tschop MH, Møller TD. Gut hormone polyagonists for the treatment of type 2 diabetes. Diabetes Obes Metab. 2016;18(2):190–201.

119. Nauck MA, Barletis E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric hormone polyglucagon and glucagon-like peptide-1(7-36) amide infused at near-physiological insulinoctic hormone and glucagon concentrations. J Clin Endocrinol Metab. 1993;76(4):1912–1917.

120. Wang Y, Wang D, Schultz PG, Wang F. Multifunctional antibody agonists targeting glucagon-like-peptide-1, glucagon, and glucose-dependent insulinoctic polypeptide receptors. Angew Chem Int Ed Engl. 2016;55(50):13475–13479.

121. Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Mafie I, Baynes KC, De Silva A, Viardot A, Alsafi A, Frost GS, Chatte MA, Bloom SR. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2016;65(4):1131–1138.

122. Palau J, Pérez-Tilve D, Seeley RJ, Alessio DA. Gastric bypass surgery enhances glucagon-like peptide-1-stimulated postprandial insulin secretion in humans. Diabetes Care. 2011;34(7):2227–2235.

123. Salehi M, Prigone RL, A Dáleus DA. Gastric bypass surgery enhances glucagon-like peptide-1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60(9):2308–2314.

124. Järveläinen V, Hietala SH, Dilcken C, Bojesen-Miller KN, Naver L, Hovrisl I, Claussen TR, Wulff BS, Worm D, Lindqvist Hansen D, Madsbad S, Holst JJ. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metabol. 2012;303(1):E227–E231.

125. Salehi M, Ghasalalizadeh A, Dáleus DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hyperglycemia after gastric bypass. Gastroenterology. 2014;146(3):669–680e2.
135. Menteis N, Vardarli I, Köthe LD, Holst JJ, Deacon CF, Theodorakis M, Meier JJ, Nauk MA. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011;60(4):1270–1276.

136. Lund A, Vilhelmsen T, Bagger JJ, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2011;300(6):E1038–E1046.

137. Daousi C, Wilding JP, Aditya S, Durham BH, Cleator J, Gault VA, Kerr BD, Harriott P, Flatt PR. Administration of synthetic human glucose-dependent insulinotropic polypeptide (GIP) on glucagon secretion in type 2 diabetes. J Mol Med (Berl). 2017;95(12):195–201.

138. GIPR co-agonist secretion in type 2 diabetes. Mol Metab. 2017;6(5):440–446.

139. Kim JA, Lee SH, Choi IY, Kim YH, Lee YM, Kwon SC. Neuroprotective effects of HM15211, a novel long-acting GLP-1/glucagon/GIP triple agonist in the MPTP Parkinson’s disease mouse model. American Diabetes Association’s 77th Scientific Sessions; June 9–13, 2017; San Diego, CA.

140. Choi IY, Lee JS, Kim JK, Park YJ, Jung SY, Kim YH. Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1/glucagon/GIP triple-agonist (HM152111). American Diabetes Association’s 77th Scientific Session; June 9–13, 2017; San Diego, CA.

141. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson’s disease: insulin resistance and novel agents of neuroprotection. Brain. 2013;136(Pt. 2):374–384.

142. Holst JJ, Weyer Albrechtsen NJ, Pedersen J, Knop FK. Glucagon and amino acids are linked in a mutual feedback cycle: the liver-α-cell axis. Diabetes. 2017;66(2):235–240.

Acknowledgments
Financial Support: This work was supported by American Diabetes Association Award 1-18-JDF-007 (to JEC).
Correspondence and Reprint Requests: Jonathan E. Campbell, PhD, Duke Molecular Physiology Institute, Duke University, 300 North Duke Street, Durham, North Carolina 27701. E-mail: jonathan.campbell1@duke.edu
Disclosure Summary: B.F. and R.D.D. are current employees of Novo Nordisk. The remaining authors have nothing to disclose.

Abbreviations
Aib, aminoisobutyric acid; CNS, central nervous system; DIO, diet-induced obesity; DPP4, dipeptidyl peptidase-4; DPP4i, dipeptidyl peptidase-4 inhibitors; FG21, fibroblast growth factor 21; GPCR, glucagon receptor; GIP, glucose-dependent insulinotropic polypeptide; GIP, glucagon receptor; GLP-1, glucagon-like peptide 1; GLP-1R, glucagon-like peptide 1 receptor; GPCR, G protein–coupled receptor; Hba1c, hemoglobin A1c; NASH, nonalcoholic steatohepatitis; SAR, structure–activity relationship; T2D, type 2 diabetes.